This drug blocks the Ras/c-Raf interaction and inhibits activation of the ERK1/2 signaling pathway (Pan et al., 2008), thereby inactivating matrix metalloproteinase-2 and inhibiting growth and metastasis of cancer cells. Here, RAF1 is linked to cancer.